Pediatrix Medical Group, Inc. (NYSE:MD) Shares Acquired by State Street Corp

State Street Corp raised its position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,540,791 shares of the company's stock after purchasing an additional 50,597 shares during the period. State Street Corp owned 4.12% of Pediatrix Medical Group worth $41,038,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Quest Partners LLC boosted its holdings in shares of Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company's stock valued at $35,000 after buying an additional 622 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Pediatrix Medical Group by 3.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company's stock valued at $245,000 after acquiring an additional 1,088 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after acquiring an additional 1,524 shares in the last quarter. Quarry LP grew its holdings in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company's stock worth $55,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Pediatrix Medical Group by 0.5% during the second quarter. Bank of Montreal Can now owns 415,110 shares of the company's stock worth $3,196,000 after purchasing an additional 2,083 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the firm's stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company's stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

MD has been the topic of a number of recent research reports. StockNews.com cut shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating in a report on Thursday. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Jefferies Financial Group increased their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, November 19th. Finally, Macquarie initiated coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They set an "outperform" rating and a $18.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $16.42.

Pediatrix Medical Group Price Performance

MD traded down $0.16 during trading on Friday, reaching $14.09. 5,048,381 shares of the stock were exchanged, compared to its average volume of 869,270. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.60, a P/E/G ratio of 2.00 and a beta of 1.57. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The business's 50 day moving average price is $14.19 and its two-hundred day moving average price is $10.97.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million during the quarter, compared to analysts' expectations of $498.87 million. During the same quarter in the previous year, the business posted $0.29 earnings per share. The firm's quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.